Korean J Health Promot KJHP Korean Journal of Health Promotion 2234-2141 2093-5676 Korean Society for Health Promotion and Disease Prevention 10.15384/kjhp.2019.19.4.171 Review Article Current Treatments on Obesity https://orcid.org/0000-0003-3291-6008 Lee Chul Jin 1 https://orcid.org/0000-0001-8912-9895 Kim Min-Jeong 2 https://orcid.org/0000-0002-6022-6058 An Sang Joon 3 Good Family Clinic, Siheung, Korea. Mihana Clinic, Yongin, Korea. Department of Neurology, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea. Corresponding author: Sang Joon An, MD, MSc. Department of Neurology, Catholic Kwandong University International St. Mary's Hospital, 25 Simgok-ro 100beon-gil, Seo-gu, Incheon 22711, Korea. Tel: +82-32-290-2994, Fax: +82-32-290-3879 neuroan@gmail.com 12 2019 31 12 2019 19 4 171 185 13 12 2019 06 01 2020 06 01 2020 Copyright © 2019 Korean Society for Health Promotion and Disease Prevention 2019 Korean Society for Health Promotion and Disease Prevention This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently, the number of obesity and diabetes mellitus have increased rapidly not only in Korea but also around the world. It is even called the new pandemic of the 21st century. In Korea, the diabetes growth rate, which exceeds the obesity growth rate, is a bigger problem. Accordingly, the simultaneous treatment of diabetes and obesity has become a global issue. In this article, we will review various obesity treatments to help diabetes remission and take a look at meaningful previous study about dietary methods for obesity. This overview includes the update of medications for obesity and the practical method for clinicians in field of obesity treatment in Korea.

 Obesity Diabetes mellitus Diabetes remission Diet therapy Anti-obesity agents Organization for Economic Cooperation and Development (OECD) Obesity update 2017 Paris OECD 2017 Organization for Economic Cooperation and Development (OECD) OECD health statistics 2017 Paris OECD 2017 Korea Centers for Disease Control and Prevention (KCDC) Nation health statistics 2017 Cheongju KCDC 2019 Korean Society for the Study of Obesity (KSSO) 2017 Obesity Fact Sheet Seoul KSSO 2017 Oh SW Recent Epidemiological changes in Korean obesity Korean J Helicobacter Up Gastrointest Res 2017 17 2 62 65 The Korean Association for Survey Research Sampling design of the 6th KNHANES and weighting adjustment of the 5th (2010–2012) Osong Korea Centers for Disease Control and Prevention 2013 Kim YH Han KD Son JW Lee SS Oh SW Kwon HS Data analytic process of a nationwide population-based study on obesity using the national health information database presented by the national health insurance service 2006-2015 J Obes Metab Syndr 2017 26 1 23 27 Kim SG Choi DS The present state of diabetes mellitus in Korea J Korean Med Assoc 2008 51 9 791 798 Centers for Disease Control and Prevention (CDC) Diabetes 2017 Report Card Atlanta CDC 2018 Korean Diabetes Association Diabetes Fact Sheet in Korea 2018 Seoul Korean Diabetes Association 2018 The Economist Heavy misconceptions, Population aged 20 years-old and above that are overweight or obese [Internet] London The Economist Accessed Dec 16, 2019 Available from: https://www.economist.com/node/21685310/mobile-frameless Kim SW Incompatibility between objective and subjective body shapes: a case in Korea J Korean Official Stat 2017 22 4 92 120 Apovian CM Okemah J O'Neil PM Body weight considerations in the management of type 2 diabetes Adv Ther 2019 36 1 44 58 Dambha-Miller H Day AJ Strelitz J Irving G Griffin SJ Behaviour change, weight loss and remission of type 2 diabetes: a community-Zbased prospective cohort study Diabet Med 2019 09 03 [Epub ahead of print] Feinmann J Type 2 diabetes: 5000 patients to test feasibility of “remission service” BMJ 2018 363 k5114 Lean ME Leslie WS Barnes AC Brosnahan N Thom G McCombie L Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial Lancet 2018 391 10120 541 551 Hallberg SJ McKenzie AL Williams PT Bhanpuri NH Peters AL Campbell WW Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study Diabetes Ther 2018 9 2 583 612 Furmli S Elmasry R Ramos M Fung J Therapeutic use of intermittent fasting for people with type 2 diabetes as an alternative to insulin BMJ Case Rep 2018 2018 bcr Wilhelmi de Toledo F Grundler F Bergouignan A Drinda S Michalsen A Safety, health improvement and well-being during a 4 to 21-day fating period in an observational study including 1422 subjects PLoS One 2019 14 1 e0209353 Taylor R Al-Mrabeh A Zhyzhneuskaya S Peters C Barnes AC Aribisala BS Hollingsworth KG Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery Cell Metab 2018 28 4 667 Lean M Hankey C Keeping it off: the challenge of weight loss maintenance Lancet Diabetes Endocrinol 2018 6 9 681 683 Lean MEJ Leslie WS Barnes AC Brosnahan N Thom G McCombie L Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial Lancet Diabetes Endocrinol 2019 7 5 344 355 Wing RR Phelan S Long-term weight loss maintenance Am J Clin Nutr 2005 82 1 222S 225S Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 de Boer IH Rue TC Cleary PA Lachin JM Molitch ME Steffes MW Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort Arch Intern Med 2011 171 5 412 420 Nathan DM Cleary PA Backlund JY Genuth SM Lachin JM Orchard TJ Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 25 2643 2653 Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up Diabetes Care 2016 39 5 686 693 Athinarayanan SJ Adams RN Hallberg SJ McKenzie AL Bhanpuri NH Campbell WW Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year non-randomized clinical trial Front Endocrinol (Lausanne) 2019 10 348 Bhanpuri NH Hallberg SJ Williams PT McKenzie AL Ballard KD Campbell WW Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study Cardiovasc Diabetol 2018 17 1 56 Frias JP Nauck MA Van J Kutner ME Cui X Benson C Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet 2018 392 10160 2180 2193 Sjöström L Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery J Intern Med 2013 273 3 219 234 Lusting RH Fat chance New York Penguin Group (USA) LLC 2012 Bray GA How bad is fructose? Am J Clin Nutr 2007 86 4 895 896 Lustig RH Schmidt LA Brindis CD Public health: the toxic truth about sugar Nature 2012 482 7383 27 29 van Buul VJ Tappy L Brouns FJ Misconceptions about fructosecontaining sugars and their role in the obesity epidemic Nutr Res Rev 2014 27 1 119 113 Lustig RH Mulligan K Noworolski SM Tai VW Wen MJ Erkin-Cakmak A Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome Obesity (Silver Spring) 2016 24 2 453 460 Williams KJ Wu X Imbalanced insulin action in chronic over nutrition: clinical harm, molecular mechanisms, and a way forward Atherosclerosis 2016 247 225 282 K Hall KD Sacks G Chandramohan D Chow CC Wang YC Gortmaker SL Quantification of the effect of energy imbalance on bodyweight Lancet 2011 378 9793 826 837 Walmart Prices and nutritional content of foods [Internet] Philadelphia Walmart 2014 Accessed Nov 6, 2014 Available from: http://www.walmart.com Stroebele N Hill JO Willich SN Identifying the energy gap in the German population using results from representative national health surveys (1985-2002) Public Health Nutr 2011 14 1 44 48 Ogden CL Fryar CD Carroll MD Flegal KM Mean body weight, height, and body mass index, United States 1960-2002 Adv Data 2004 347 1 17 Champagne CM Han H Bajpeyi S Rood J Johnson WD Lammi-Keefe CJ Day-to-day variation in food intake and energy expenditure in healthy women: the Dietitian II Study J Acad Nutr Diet 2013 113 11 1532 1538 Fildes A Charlton J Rudisill C Littlejohns P Prevost AT Gulliford MC Probability of an obese person attaining normal body weight: cohort study using electronic health records Am J Public Health 2015 105 9 e54 e59 Sumithran P Prendergast LA Delbridge E Purcell K Shulkes A Kriketos A Long term persistence of hormonal adaptiation to weight loss N Engl J Med 2011 365 17 1597 1604 Fothergill E Guo J Howard L Kerns JC Knuth ND Brychta R Persistent metabolic adaptation 6 years after “the biggest Loser” competition Obesity (Silver Spring) 2016 24 8 1612 1619 Johansson K Neovius M Hemmingsson E Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials Am J Clin Nutr 2014 99 1 14 23 The National Weight Control Registry (NWCR) NWCR facts [Internet] Providence NWCR Accessed Dec 16, 2019 Available from: http://www.nwcr.ws/Research/default.htm Thomas JG Bond DS Phelan S Hill JO Wing RR Weightloss maintenance for 10 years in the National Weight Control Registry Am J Prev Med 2014 46 1 17 23 Soleymani T Daniel S Garvey WT Weight maintenance: challenges, tools and strategies for primary care physicians Obes Rev 2016 17 1 81 93 Gilis-Januszewska A Barengo NC Lindström J Wojtowicz E Acosta T Tuomilehto J Predictors of long term weight loss maintenance in patients at high risk of type 2 diabetes participating in a lifestyle intervention program in primary health care: The DE-PLAN study PLoS One 2018 13 3 e0194589 Snorgaard O Poulsen GM Andersen HK Astrup A Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes BMJ Open Diabetes Res Care 2017 5 1 e000354 van Wyk HJ Davis RE Davies JS A critical review of low-carbohydrate diets in people with type 2 diabetes Diabet Med 2016 33 2 148 157 Tay J Thompson CH Luscombe-Marsh ND Wycherley TP Noakes M Buckley JD Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: a 2-year randomized clinical trial Diabetes Obes Metab 2018 20 4 858 871 van Zuuren EJ Fedorowicz Z Kuijpers T Pijl H Effects of low-carbohydrate-compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments Am J Clin Nutr 2018 108 2 300 331 Naude CE Schoonees A Senekal M Young T Garner P Volmink J Low carbohydrate versus isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review and meta-analysis PLoS One 2014 9 7 e100652 Gill S Panda S A smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits Cell Metab 2015 22 5 789 798 Gabel K Hoddy KK Haggerty N Song J Kroeger CM Trepanowski JF Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: a pilot study Nutr Healthy Aging 2018 4 4 345 353 Antoni R Robertson TM Robertson MD Johnston JD A pilot feasibility study exploring the effects of a moderate time-restricted feeding intervention on energy intake, adiposity and metabolic physiology in free-living human subjects J Nutr Sci 2018 7 E22 Hutchison AT Regmi P Manoogian ENC Fleischer JG Wittert GA Panda S Time-restricted feeding improves glucose tolerance in men at risk for type 2 diabetes: a randomized crossover trial Obesity (Silver Spring) 2019 27 5 724 732 Wilkinson MJ Manoogian ENC Zadourian A Lo H Fakhouri S Shoghi A Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome Cell Metab 2019 12 2 [Epub ahead of print] Sutton EF Beyl R Early KS Cefalu WT Ravussin E Peterson CM Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes Cell Metab 2018 27 6 1212 1221.e3 Harris L Hamilton S Azevedo LB Olajide J De Brún C Waller G Intermittent fasting interventions for treatment of overweight and obesity in adults: a systematic review and meta-analysis JBI Database System Rev Implement Rep 2018 16 2 507 547 Gardner CD Kiazand A Alhassan S Kim S Stafford RS Balise RR Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z weight loss study: a randomized trial JAMA 2007 297 9 969 977 Johnston BC Kanters S Bandayrel K Wu P Naji F Siemieniuk RA Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis JAMA 2014 312 9 923 933 Gardner CD Trepanowski JF Del Gobbo LC Hauser ME Rigdon J Ioannidis JPA Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial JAMA 2018 319 7 667 679 Dehghan M Mente A Zhang X Swaminathan S Li W Mohan V Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study Lancet 2017 390 10107 2050 2062 Seidelmann SB Claggett B Cheng S Henglin M Shah A Steffen LM Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis Lancet Public Health 2018 3 9 e419 e428 huang X Zhang S Zhou H Du Z Liao X U-shaped relationship between carbohydrate intake proportion and incident atrial fibrillation J Am Coll Cardiol 2019 73 9 4 Reynolds A Mann J Cummings J Winter N Mete E Te Morenga L Carbohydrate quality and human health: a series of systematic reviews and meta-analyses Lancet 2019 393 10170 434 445 Purcell K Sumithran P Prendergast LA Bouniu CJ Delbridge E Proietto J The effect of rate of weight loss on long-term weight management: a randomised controlled trial Lancet Diabetes Endocrinol 2014 2 12 954 962 Nackers LM Ross KM Perri MG The association between rate of initial weight loss and long-term success in obesity treatment: does slow and steady win the race? Int J Behav Med 2010 17 3 161 167 Unick JL Neiberg RH Hogan PE Cheskin LJ Dutton GR Jeffery R Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later Obesity (Silver Spring) 2015 23 7 1353 1356 Sievert K Hussain SM Page MJ Wang Y Hughes HJ Malek M Effect of breakfast on weight and energy intake: systematic review and meta-analysis of randomised controlled trials BMJ 2019 364 l42 Yang Y Evidence based exercise to control weight J Korean Med Assoc 2017 60 10 806 816 McClernon FJ Yancy WS Jr Eberstein JA Atkins RC Westman EC The effects of a low-carbohydrate ketogenic diet and a low-fat diet on mood, hunger, and other self-reported symptoms Obesity (Silver Spring) 2007 15 1 182 187 Hendricks EJ Rothman RB Greenway FL How physician obesity specialists use drugs to treat obesity Obesity (Silver Spring) 2009 17 9 1730 1735 Thomas CE Mauer EA Shukla AP Rathi S Aronne LJ Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s Obesity (Silver Spring) 2016 24 9 1955 1961 Novo Nordisk Novo Nordisk Annual Report 2018 Bagsværd Novo Nordisk 2019 Lee SJ Serious Abuse of Psychotropic Anti-Obesity Drugs; Suspect of over-prescription by doctor [Internet] Seoul MedicalTimes 2013 Accessed MON DAY, YEAR Avaliable from: http://www.medicaltimes.com/Users/News/NewsView.html?ID=1085905 O'Neil PM Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss inpatientswithobesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial Lancet 2018 392 10148 637 649 Mancini MC de Melo ME The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg Diabetol Metab Syndr 2017 9 44 Munro JF MacCuish AC Wilson EM Duncan LJ Comparison of continuous and intermittent anorectic therapy in obesity Br Med J 1968 1 5588 352 354 Aronne LJ Wadden TA Peterson C Winslow D Odeh S Gadde KM Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults Obesity (Silver Spring) 2013 21 11 2163 2171 Garvey WT Ryan DH Bohannon NJ Kushner RF Rueger M Dvorak RV Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release Diabetes Care 2014 37 12 3309 3316 Hollander P Bays HE Rosenstock J Frustaci ME Fung A Vercruysse F Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial Diabetes Care 2017 40 5 632 639 Smith SR Garvey WT Greenway FL Zhou S Fain R Pilson R Coadministration of lorcaserin and phentermine for weight management: a 12-week, randomized, pilot safety study Obesity (Silver Spring) 2017 25 5 857 865 Moldovan CP Weldon AJ Daher NS Schneider LE Bellinger DL Berk LS Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings Obesity (Silver Spring) 2016 24 11 2344 2350 Lewis KH Fischer H Ard J Barton L Bessesen DH Daley MF Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort Obesity (Silver Spring) 2019 27 4 591 602 Onakpoya IJ Heneghan CJ Aronson JK Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review BMC Med 2016 14 1 191 Heck AM Yanovski JA Calis KA Orlistat, a new lipase inhibitor for the management of obesity Pharmacotherapy 2000 20 3 270 279 Torgerson JS Hauptman J Boldrin MN Sjöström L XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 2004 27 1 155 161 Patel DK Stanford FC Safety and tolerability of new-generation anti-obesity medications: a narrative review Postgrad Med 2018 130 2 173 182 Weir MA Beyea MM Gomes T Juurlink DN Mamdani M Blake PG Orlistat and acute kidney injury: an analysis of 953 patients Arch Intern Med 2011 171 7 703 704 Kopelman P Groot Gde H Rissanen A Rossner S Toubro S Palmer R Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical) Obesity (Silver Spring) 2010 18 1 108 115 Bohula EA Wiviott SD McGuire DK Inzucchi SE Kuder J Im K Cardiovascular safety of Lorcaserin in overweight or obese patients N Engl J Med 2018 379 12 1107 1117 Bohula EA Scirica BM Fanola C Inzucchi SE Keech A McGuire DK Design and rationale for the cardiovascular and metabolic effects of lorcaserin in overweight and obese patients-thrombolysis in myocardial infarction 61 (CAMELLIATIMI 61) trial Am Heart J 2018 202 39 48 Farr OM Upadhyay J Gavrieli A Camp M Spyrou N Kaye H Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo-controlled, double-blind clinical trial Diabetes 2016 65 10 2943 2953 Allison DB Gadde KM Garvey WT Peterson CA Schwiers ML Najarian T Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2012 20 2 330 342 Gadde KM Allison DB Ryan DH Peterson CA Troupin B Schwiers ML Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 2011 377 9774 1341 1352 Garvey WT Ryan DH Look M Gadde KM Allison DB Peterson CA Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study Am J Clin Nutr 2012 95 2 297 308 Winslow DH Bowden CH DiDonato KP McCullough PA A randomized, double-blind, placebo-controlled study of anoral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults Sleep 2012 35 11 1529 1539 Guerdjikova AI Williams S Blom TJ Mori N McElroy SL Combination phentermine-topiramate extended release for the treatment of binge eating disorder: an open-label, Prospective Study Innov Clin Neurosci 2018 15 5-6 17 21 Ritchey ME Harding A Hunter S Peterson C Sager PT Kowey PR Cardiovascular safety during and after use of phentermine and topiramate J Clin Endocrinol Metab 2019 104 2 513 522 Ard JD Beavers DP Hale E Miller G McNatt S Fernandez A Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m2 or more Surg Obes Relat Dis 2019 15 7 1039 1043 Pi-Sunyer X Astrup A Fujioka K Greenway F Halpern A Krempf M A randomized, controlled trial of 3.0 mg of liraglutide in weight management N Engl J Med 2015 373 1 11 22 Wadden TA Hollander P Klein S Niswender K Woo V Hale PM Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study Int J Obes (Lond) 2013 37 11 1443 1451 Davies MJ Bergenstal R Bode B Kushner RF Lewin A Skjøth TV Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial JAMA 2015 314 7 687 699 Blackman A Foster GD Zammit G Rosenberg R Aronne L Wadden T Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial Int J Obes (Lond) 2016 40 8 1310 1319 Hegedüs L Sherman SI Tuttle RM von Scholten BJ Rasmussen S Karsbøl JD No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to Liraglutide for up to 5 years in the LEADER trial Diabetes Care 2018 41 3 620 622 Fujioka K O'Neil PM Davies M Greenway F C W Lau D Claudius B Early weight loss with liraglutide 30 mg predicts 1-year weight loss and is associated with improvements in clinical markers Obesity (Silver Spring) 2016 24 11 2278 2288 Iepsen EW Lundgren J Dirksen C Jensen JE Pedersen O Hansen T Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss Int J Obes (Lond) 2015 39 5 834 841 de Boer SA Lefrandt JD Petersen JF Boersma HH Mulder DJ Hoogenberg K The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour Int J Clin Pharm 2016 38 1 144 151 Sharma A Ambrosy AP DeVore AD Margulies KB McNulty SE Mentz RJ Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: Insights from the FIGHT trial ESC Heart Fail 2018 5 6 1035 1043 Larsen JR Vedtofte L Jakobsen MSL Jespersen HR Jakobsen MI Svensson CK Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial JAMA Psychiatry 2017 74 7 719 728 Simonds SE Pryor JT Koegler FH Buch-Rasmussen AS Kelly LE Grove KL Determining the effects of combined liraglutide and phentermine on metabolic parameters, blood pressure and heart rate in lean and obese male mice Diabetes 2019 68 4 683 695 Dunn E A retrospective comparative analysis on the effectiveness of pharmacologic weight loss [dissertation] Lexington University of Kentucky College of Nursing 2018 English Greig SL Keating GM Naltrexone ER/bupropion ER: a review in obesity management Drugs 2015 75 11 1269 1280 Greenway FL Fujioka K Plodkowski RA Mudaliar S Guttadauria M Erickson J Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2010 376 9741 595 605 Apovian CM Aronne L Rubino D Still C Wyatt H Burns C A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity (Silver Spring) 2013 21 5 935 943 Hollander P Gupta AK Plodkowski R Greenway F Bays H Burns C Effects of naltrexone sustained-release/bupropion sustained release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes Diabetes Care 2013 36 12 4022 4029 Wadden TA Foreyt JP Foster GD Hill JO Klein S O'Neil PM Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial Obesity (Silver Spring) 2011 19 1 110 120 Srivastava G Apovian C Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon Curr Obes Rep 2018 7 2 147 161 Gaich G Chien JY Fu H Glass LC Deeg MA Holland WL The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes Cell Metab 2013 18 3 333 340 Azegami T uki Y Sawada S Mejima M Ishige K Akiyoshi K Nanogel-based nasal ghrelin vaccine prevents obesity Mucosal Immunol 2017 10 5 1351 1360 Huo L Lyons J Magliano DJ Infectious and environmental influences on the obesity epidemic Curr Obes Rep 2016 5 3 375 382 Hendricks EJ Off-label drugs for weight management Diabetes Metab Syndr Obes 2017 10 223 234 Increasing prevalence of obesity from 2009 to 2015 in Korea.<xref ref-type="bibr" rid="B4">4)</xref> Heavy misconceptions about obesity of all over the world.<xref ref-type="bibr" rid="B11">11)</xref> Remission of type 2 diabetes after primary care for weight management shown by DiRECT study.<xref ref-type="bibr" rid="B16">16)</xref> DiRECT, Diabetes Remission Clinical Trial; CI, confidence interval. Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes shown by Low Carb High Fat (LCHF) study for 2 years.<xref ref-type="bibr" rid="B17">17)</xref> HbA1c, hemoglobin A1c. Association between estimated percentage energy from fat versus carbohydrate and total mortality shown by Prospective Urban Rural Epidemiology (PURE) study.<xref ref-type="bibr" rid="B66">66)</xref> HR, hazard ratio. (A, B) U-shaped association between percentage of energy from carbohydrate and all-cause mortality in the Atherosclerosis Risk in Communities (ARIC) (line) and Prospective Urban Rural Epidemiology (PURE) (dotted line) cohort studies.<xref ref-type="bibr" rid="B67">67)</xref> Mechanism of anti-obesity medication about homeostatic appetite and hedonic appetite.<xref ref-type="bibr" rid="B81">81)</xref> ARC, arcuate nucleus; GABA, gamma-aminobutyric acid. Four large SCALE randomized multicenter phase III trial in liraglutide (SCALE Obesity and Prediabetes, SCALE Diabetes, SCALE Sleep Apnea, and SCALE Maintenance).<xref ref-type="bibr" rid="B105">105</xref><xref ref-type="bibr" rid="B106">106</xref><xref ref-type="bibr" rid="B107">107</xref><xref ref-type="bibr" rid="B108">108)</xref>